Roth Capital reaffirms its Buy rating and $146 price target on Ligand Pharmaceuticals (Nasdaq: LGND) following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE